Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Ibs, Mabs and More: Changing the Treatment Landscape for Chronic Lymphocytic Leukemia


Description:
CLL is the most prevalent adult leukemia in Western countries with an estimated 18,960 new diagnoses and an estimated 4,660 deaths from disease in the United States in 2016. The treatment landscape of CLL has changed dramatically over recent years, due to a better understanding of the pathobiology of CLL, and the development and approval of several targeted therapies.  While chemoimmunotherapy, such as combination therapy with fludarabine, cyclophosphamide and rituximab (FCR), remains first line treatment for young, fit patients without 17p deletion disease, targeted therapies have emerged as frontline treatment for patients with 17p deletion regardless of age as well as older patients who are not candidates for FCR.  Targeted therapies also play an important role in patients with relapsed/refractory disease. This presentation will focus on ibrutinib, idelalisib, and obinutuzumab for the treatment of patients with CLL. The mechanism of action, clinical data, role in therapy, and toxicity profiles will be discussed. Additionally, there are a number of promising new therapies in the pipeline that will be introduced. It is important for pharmacists to understand current treatment recommendations and side effect management for the various new agents available for CLL.  
 

Objectives:

  • Evaluate the efficacy of targeted therapies and their place in therapy for patients with CLL.
  • Discuss toxicities and management of toxicities associated with targeted therapies for CLL.
  • Identify emerging novel therapies for patients with CLL.
Activity Number:
0280-0000-16-076-H01-P

This recorded activity is a based on a live program that was offered on October 14, 2016 in Burlington, MA.  
Participants who received credit for the live program should not claim credit for this web based presentation.
 
System Requirements for Participants:
Operating system:  Windows XP, Vista or 7  MAC OS X  Latest Version of Adobe Reader
Browser Internet Explorer 8.0 or above  Google Chrome 16.0 or above  Firefox 7.0 or above  Safari 5.0 or above
 

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Activity Type

  • Application Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
American Health Resources is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education

Requirements for CE Credit

  • Complete the pre-test
  • Review the content of this activity
  • Successfully complete the post-test with a score of 80% or higher 
  • Complete the evaluation
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation is completed.
 
Pharmacists - Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits will NOT be reported.

Support/Credits

Disclosures:
The presenter is Hillary Prescott, PharmD; Clinical Pharmacy Specialist, Dana-Farber Cancer Institute, Boston, MA.
Dr. Prescott does not have any relevant financial relationships with any commercial interests.
 
The reviewer is Ali McBride, PharmD, MS, BCPS, BCOP; Clinical Coordinator Hematology/Oncology,
The University of Arizona Cancer Center, Tucson, AZ.  
Dr. McBride does not have any relevant financial relationships with any commercial interests.
 
Support for This Activity:
Educational grant funding was received from Pharmacyclics LLC and Janssen Biotech, Inc
This activity is supported by the Association of Community Cancer Centers (ACCC)
 
American Health Resources assesses conflict of interest with its instructors, reviewers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are resolved by American Health Resources for fair balance and scientific objectivity.
 
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  American Health Resources does not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of American Health Resources.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

 

CLL is the most prevalent adult leukemia in Western countries with an estimated 18,960 new diagnoses and an estimated 4,660 deaths from disease in the United States in 2016. The treatment landscape of CLL has changed dramatically over recent years, due to a better understanding of the pathobiology of CLL, and the development and approval of several targeted therapies.  While chemoimmunotherapy, such as combination therapy with fludarabine, cyclophosphamide and rituximab (FCR), remains first line treatment for young, fit patients without 17p deletion disease, targeted therapies have emerged as frontline treatment for patients with 17p deletion regardless of age as well as older patients who are not candidates for FCR.  Targeted therapies also play an important role in patients with relapsed/refractory disease. This presentation will focus on ibrutinib, idelalisib, and obinutuzumab for the treatment of patients with CLL. The mechanism of action, clinical data, role in therapy, and toxicity profiles will be discussed. Additionally, there are a number of promising new therapies in the pipeline that will be introduced. It is important for pharmacists to understand current treatment recommendations and side effect management for the various new agents available for CLL.  
 

Objectives

  • Evaluate the efficacy of targeted therapies and their place in therapy for patients with CLL.
  • Discuss toxicities and management of toxicities associated with targeted therapies for CLL.
  • Identify emerging novel therapies for patients with CLL.

Speaker(s)/Author(s)

Hillary Prescott, PharmD picture

Hillary Prescott, PharmD
Clinical Pharmacy Specialist, Dana-Farber Cancer Institute


Brief Bio : Hillary Prescott, PharmD, is currently an Oncology Clinical Pharmacy Specialist at Dana-Farber Cancer Institute in Boston, MA. Dr. Prescott received a PharmD from the University of Rhode Island. She then completed a Pharmacy Practice Residency at the Medical College of Virginia followed by a Hematology/Oncology Specialty Residency at the University of North Carolina Medical Center. Prior to Dana-Farber, she practiced as an Oncology Clinical Pharmacy Specialist in Leukemia at MD Anderson Cancer Center for close to 10 years. She is a member of committees within the NCCN and HOPA, and has authored review articles and given presentations both nationally and internationally.

Activity Number

0280-0000-16-076-H01-P

Release Date: Nov 5, 2016
Credit Expiration Date: Nov 5, 2018

CE Hours

1.00

Fee

$0.00